Breaking News

Lonza, BioWa Ink License Pact with Pfizer

July 30, 2013

Will use POTELLIGENT CHOK1SV cell line

BioWa, Inc. and Lonza have entered into a research agreement with Pfizer for the use of their POTELLIGENT CHOK1SV cell line in the R&D of multiple antibodies in Pfizer’s pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT technology with Lonza’s GS Gene Expression System, which includes the host cell line, CHOK1SV.
 
“We are pleased that the core value of POTELLIGENT Technology has been recognized by a global pharmaceutical company such as Pfizer, and are excited to work together with Pfizer on their innovative antibody research pipelines.” said Yasunori Yamaguchi, Ph.D., president and chief executive officer of BioWa.
 
“The GS System and the CHOK1SV Cell Line continue to be a gold standard for therapeutic antibody development.  We are proud to be able to support Pfizer with this technology for their ongoing development portfolio.” said Karen Fallen, vice president, head of licensing, Lonza Custom Development Services.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.